109
Participants
Start Date
November 30, 2020
Primary Completion Date
May 23, 2022
Study Completion Date
February 7, 2023
Adavosertib
The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Research Site, Nice
Research Site, New York
Research Site, The Bronx
Research Site, Marseille
Research Site, A Coruña
Research Site, Milan
Research Site, Dijon
Research Site, Pozuelo de Alarcón
Research Site, Saint-Herblain
Research Site, Iowa City
Research Site, Rochester
Research Site, Pierre-Bénite
Research Site, Covington
Research Site, Aurora
Research Site, Napoli
Research Site, West Hollywood
Research Site, Duarte
Research Site, Burbank
Research Site, La Jolla
Research Site, Vancouver
Research Site, Spokane
Research Site, Boston
Research Site, New Brunswick
Research Site, Toronto
Research Site, Roma
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY